SVR and RVR rates according to INF-L3 and HCV genotype.

<p><b>(A)</b> SVR rates in relation to IFNL3 genotype (PP analysis). (B) RVR rates in relation to IFNL3 genotype (PP analysis). (C) SVR rates in relation to IFNL3 genotype in HCV genotype 2 patients. (D) SVR rates in relation to IFNL3 genotype in HCV genotype 3 patients. (E) RVR rates in relation to IFNL3 genotype in HCV genotype 3 patients. (F) RVR rates in relation to IFNL3 genotype in HCV genotype 2 patients.</p

Flow chart of patients with available IFNL3 and IFN-L4 genotype.

<p>Flow chart of patients with available IFNL3 and IFN-L4 genotype.</p

HCV RNA levels at baseline according to IFNL3 genotypes.

<p>(A) HCV RNA levels at baseline for patients with favourable and non-favorable rs1297860 genotype. (B) HCV RNA levels at baseline for patients with favourable and non-favorable rs8099917 genotype.</p

RVR in HCV genotype 3 according to baseline viral load in relation to IFNL3 genotype.

<p>RVR in HCV genotype 3 according to baseline viral load in relation to IFNL3 genotype.</p

CONSORT flowchart for the OPTEX trial.

<p>CONSORT flowchart for the OPTEX trial.</p

Baseline characteristics of all randomized patients at study initiation.

<p>* In Delgard et al., 400.000IU/mL was used as cut-off for high and low viral load</p><p>Baseline characteristics of all randomized patients at study initiation.</p

SF-36 Physical and Mental Health.

<p>SF-36 Physical and Mental Health.</p

Subgroupanalysis.

<p>Subgroupanalysis.</p

Study design of the OPTEX 2/3 trial.

<p>Study design of the OPTEX 2/3 trial.</p

Virological response rates at EOT, FU12 and FU24 in the ITT, mITT and completer population.

<p>Virological response rates at EOT, FU12 and FU24 in the ITT, mITT and completer population.</p